Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, Optics Valley Industry Investment, CDBI Partners, CreditEase, Ancheng Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NeuLive Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuLive Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuLive Medical
Developer of neurological devices designed to treat ischemic stroke, pain, epilepsy, Parkinson's, obsessive-compulsive disorder, and other neurological diseases. The company focuses on stroke and hemorrhage products such as dense mesh stents, auxiliary stents, intratumoral embolization devices, aspiration devices, catheters, guide wires and other stroke ischemia products, providing patients with domestic alternatives to treat neurological diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 2
- Website
- neulive.cn/
- Ownership
- Privately Held (backing)
NeuLive Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuLive Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuLive Medical in its N-PORT filings yet. We sweep new filings monthly.